Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Tavneos Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.04.52

    Tavneos (avacopan) Coverage Policy

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.04.52 alerts

    Get alerted when Policy 05.04.52 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs coverage and prior authorization for Tavneos (avacopan) as adjunctive treatment for adults with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis or microscopic polyangiitis. Coverage requires documented clinical criteria, specialist prescribing or consultation for initial requests, and applicable benefit eligibility.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyTavneos (avacopan) Coverage Policy
    Policy CodePolicy 05.04.52
    Change TypeNo material change
    Effective DateAugust 20, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionFor initial requests, submit documentation of positive anti-PR3 or anti-MPO antibody testing and a pretreatment objective assessment of the member’s disease.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsAuthorization period
    30 mg twice dailyFDA-recommended dose
    180/30 daysQuantity limit
    18 yearsMinimum initial authorization age

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Anti-PR3 or anti-MPO positiveRequired antibody history

    Coverage Criteria

    Initial Therapy Criteria

    Authorization of 12 months may be granted when all of the following criteria are met.

    Initial therapy

    • Disease and age: The member has severe active ANCA-associated vasculitis involving GPA or MPA and is 18 years of age or older.Age >= 18 years
    • Concomitant therapy: Tavneos is used in combination with standard therapy.

      Examples include rituximab, cyclophosphamide, methotrexate, azathioprine, and mycophenolate mofetil.

    • Antibody testing: The member has a history of testing positive for anti-PR3 or anti-MPO antibody.Positive anti-PR3 or anti-MPO antibody
    • Pretreatment assessment: Documentation includes a pretreatment objective assessment of the most impactful aspects of the member's ANCA-associated vasculitis.

      Examples include renal, pulmonary, or neurologic involvement.

    Continuation Therapy Criteria

    Authorization of 12 months may be granted for continued treatment when the member achieves or maintains a positive clinical response.

    Continuation therapy

    • Clinical response: The most impactful aspects of the member's ANCA-associated vasculitis have stabilized or improved.Stabilization or improvement

      Examples include renal, pulmonary, or neurologic involvement.

    Tavneos is considered not medically necessary when the member does not meet the applicable initial or continuation coverage criteria, including the requirement for a positive clinical response during continued treatment.

    Procedures and Billing Codes

    Procedures and Billing Codesmixed
    N/ANot applicable

    Provider Requirements and Documentation

    Prior Authorization

    Specialist Prescriber or Consultation Required

    For initial requests, Tavneos must be prescribed by or used in consultation with an eligible specialist experienced in ANCA-associated vasculitis.

    • Eligible specialists include a nephrologist, pulmonologist, rheumatologist, or specialist in the treatment of ANCA-associated vasculitis (GPA and MPA).
    Step Therapy

    Use With Standard Therapy

    Tavneos must be used in combination with standard therapy for severe active ANCA-associated vasculitis.

    • Examples of standard therapy include rituximab, cyclophosphamide, methotrexate, azathioprine, or mycophenolate mofetil.

    Background

    ANCA-associated vasculitis (AAV) is an autoimmune group of diseases that causes inflammation of small blood vessels and may lead to severe, potentially life-threatening organ dysfunction. This policy addresses granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), which are commonly associated with anti-PR3 and anti-MPO antibodies, respectively. Tavneos (avacopan) is a C5a receptor antagonist used as adjunctive treatment with standard therapy, including glucocorticoids; it does not eliminate the need for glucocorticoid use.

    Definitions and Abbreviations

    ANCA-associated vasculitis (AAV)
    TermANCA-associated vasculitis (AAV)
    DefinitionAn autoimmune small-vessel vasculitis associated with anti-neutrophil cytoplasmic antibodies.
    Potential complicationsMay cause organ dysfunction, including renal, pulmonary, and neurologic complications.
    Granulomatosis with polyangiitis (GPA)
    TermGranulomatosis with polyangiitis (GPA)
    ClassificationA form of ANCA-associated vasculitis.
    Policy relevance

    Initial Approval Criteria

    Initial Approval

    Authorization of 12 months may be granted for treatment of severe active ANCA-associated vasculitis involving GPA or MPA when all of the following criteria are met.

    Initial approval

    • Disease and age: The member has severe active ANCA-associated vasculitis involving GPA or MPA and is 18 years of age or older.Age >= 18 years
    • Standard therapy: Tavneos is used in combination with standard therapy.

      Examples include rituximab, cyclophosphamide, methotrexate, azathioprine, and mycophenolate mofetil.

    • Serology: The member has a history of testing positive for anti-PR3 or anti-MPO antibody.

    Continuation Approval Criteria

    Continuation Approval

    Authorization of 12 months may be granted for continued treatment when a positive clinical response is achieved or maintained.

    Continuation approval

    • Clinical response: The most impactful aspects of the member's ANCA-associated vasculitis have stabilized or improved.Stabilization or improvement

    Concurrent Standard Therapy

    StepRequirementStandard therapy examples
    1Use Tavneos in combination with standard therapy.Rituximab; cyclophosphamide; methotrexate; azathioprine; mycophenolate mofetil

    Dose and Quantity Limits

    Standard quantity limit
    MedicationTavneos (avacopan) 10 mg capsule
    Standard quantity limit180 capsules
    Supply periodPer 30 days
    FDA-recommended dose
    MedicationTavneos (avacopan)
    FDA-recommended dose30 mg twice daily
    FrequencyTwice daily
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyTavneos (avacopan) Coverage Policy
    Policy CodePolicy 05.04.52
    Change TypeNo material change
    Effective DateAugust 20, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionFor initial requests, submit documentation of positive anti-PR3 or anti-MPO antibody testing and a pretreatment objective assessment of the member’s disease.
    SourceLink
    On This Page
    Coverage CriteriaProcedures and Billing CodesProvider Requirements and DocumentationBackgroundDefinitions and AbbreviationsInitial Approval CriteriaContinuation Approval CriteriaConcurrent Standard TherapyDose and Quantity Limits
    Documentation Required

    Initial Clinical Documentation Required

    Initial requests must include documentation supporting the diagnosis and baseline disease severity.

    • Chart notes or medical records showing a history of a positive serum assay for anti-proteinase 3 (anti-PR3) or anti-myeloperoxidase (anti-MPO) antibody.
    • Chart notes or medical records documenting a pre-treatment objective assessment of the most impactful aspects of the member's ANCA-associated vasculitis, such as renal, pulmonary, or neurologic involvement.
    Documentation Required

    Continuation Clinical Documentation Required

    Continuation requests must document that the member has achieved or maintained a positive clinical response to Tavneos.

    • Submit chart notes or medical records showing stabilization or improvement in the most impactful aspects of the member's ANCA-associated vasculitis, such as renal, pulmonary, or neurologic involvement.
    Denial Risk

    Criteria Not Met

    Tavneos is considered not medically necessary when the member does not meet the applicable initial or continuation criteria.

    • This includes failure to meet the requirements for severe active ANCA-associated vasculitis, eligible age, combination use with standard therapy, positive anti-PR3 or anti-MPO antibody testing, required objective assessment, or documented clinical response for continuation therapy.
    Denial Risk

    Initial Criteria Incomplete

    Initial authorization requirements are incomplete when the request does not establish all required clinical and treatment conditions.

    • Severe active ANCA-associated vasculitis (GPA or MPA) is not documented.
    • The member is younger than 18 years of age.
    • Tavneos is not being used in combination with standard therapy.
    • A history of positive anti-PR3 or anti-MPO antibody testing is not documented.
    • Pre-treatment objective assessment of the most impactful disease manifestations is not documented.
    Included in the FDA-approved indication for Tavneos as part of severe active ANCA-associated vasculitis treated with standard therapy, including glucocorticoids.
    Microscopic polyangiitis (MPA)
    TermMicroscopic polyangiitis (MPA)
    ClassificationA form of ANCA-associated vasculitis.
    Policy relevanceIncluded in the FDA-approved indication for Tavneos as part of severe active ANCA-associated vasculitis treated with standard therapy, including glucocorticoids.
    GTI
    AbbreviationGTI
    ExpansionGlucocorticoid Toxicity Index
    ContextUsed as an outcome measure in the ADVOCATE 2021 results.
    Positive anti-PR3 or anti-MPO antibody
  1. Objective baseline assessment: Documentation includes a pretreatment objective assessment of the most impactful aspects of the member's ANCA-associated vasculitis.

    Examples include renal, pulmonary, or neurologic involvement.